Calving season, a crucial period for beef producers, may see a reduction in duration thanks to a new breakthrough originating from the University of Saskatchewan. Cetrorelix, a hormone medication commonly utilized in human in vitro fertilization (IVF), is poised to enter the market for cattle following successful research conducted at the university. Dr. Jaswant Singh, a veterinary medicine expert and researcher at the Western College of Veterinary Medicine, stumbled upon this development in an unrelated study eight years ago, giving credit to graduate students Dylan Farmer and Carlos Leonardi for their contributions.
Singh expressed enthusiasm about the drug’s potential, stating, “We tested this on 200 cows with excellent results. This drug is a significant discovery we have long sought after, and we are thrilled about its forthcoming availability. Currently, the drug is in the discovery phase.”
The drug functions as a method for synchronizing ovulation, prompting cows to conceive through IVF within a short timeframe, leading to synchronized pregnancies and potentially simultaneous births. While various synchronization methods exist, Cetrorelix has the potential to become a preferred option.
By narrowing the calving window, potentially from two months to one, labor costs can be reduced, and animal management can be improved, according to Singh. He highlighted the benefits of early calving in enhancing calf weaning weights and increasing farmers’ profits.
Garner Deobald, a beef rancher and marketing manager at BoviGen Genetic Services in Saskatchewan, expressed keen interest in integrating Cetrorelix into their breeding practices, emphasizing the value it could bring to both their operations and clients. He emphasized the industry’s readiness to adopt beneficial innovations swiftly.
The introduction of the new drug could elevate artificial insemination as a more enticing breeding method compared to traditional approaches, offering advantages in genetic selection and calf predictability. Singh mentioned that the university has filed a patent for the drug and is collaborating with pharmaceutical firms for its commercialization.
Singh expressed optimism about the drug’s future adoption, anticipating increased artificial insemination usage among farmers worldwide due to its promising efficacy, reasonable cost, and progress in regulatory approvals.